Study of bcl-2 and p53 Protein Expression in Prostatic Cancer.
- Author:
Seok Heun JANG
1
;
Bong Suk SHIM
Author Information
1. Department of Urology, College of Medicine, Ewha Womans University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prostatic cancer;
bcl-2;
p53
- MeSH:
Apoptosis;
Gene Expression;
Prostatic Neoplasms*
- From:Korean Journal of Urology
1998;39(1):37-40
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: bcl-2 and p53 are known to act as a regulator of apoptosis in prostatic cancer and we evaluated the significance of these gene expressions and correlation with prognostic factors in prostatic cancer MATERIALS AND METHODS: Forty-five formalin-fixed and paraffin-embedded samples of histologically confirmed prostatic cancer, examined using immunohistochemical staining for the two gene products and the expression related to the grade and stage. RESULTS: We found that positive staining for bel-2 was 46.7%(21/45) and p53 was 31.8%(17/45). As compared to the Gleason grade, positive staining for bel-2 and p53 was 14.3%(2/14), 7.1%(1/14) at low grade, 40.0%(6/15), 40.0% (6/15) at intermediate grade, 81.3%(13/16), 62.5%(10/16) at high grade, respectively. It was significant difference(p<0.05). And, as compared to the stage, positive staining for bel-2 and p53 was 0%(0/7), 0%(0/7) at stage A, 33.3%(4/12), 16.7%(2/12) at stage B, 54.5%(6/11), 45.5%(5/11) at stage C, 73.3%(11/15), 66.7%(10/l5) at stage D, respectively. It was significant difference (p<0.05). CONCLUSIONS: These results suggest that bcl-2 and p53 expression are associated with the grade and stage of prostatic cancer, and to use them as the prognostic factor of prostatic canecr, further study is needed at the molecular level.
